

BCR-ABL1 Mutation Analysis for Tyrosine Kinase Inhibitor Resistance

Last Literature Review: August 2020 Last Update: June 2024

BCR-ABL1 mutations may cause resistance to tyrosine kinase inhibitor (TKI) therapy in patients with either chronic myelogenous leukemia (CML) or Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). Testing should be performed for patients with an established diagnosis of a *BCR-ABL1*-positive leukemia to guide treatment decisions.

Disease Overview

Treatment Issues

Chronic Myelogenous Leukemia

- CML is characterized by *BCR-ABL1* translocations
- Initial treatment protocol is TKI therapy
 - Imatinib (Gleevec) inhibits tyrosine kinase activity caused by the *BCR-ABL1* gene fusion
 - Dasatinib (Sprycel) is a dual specific SRC/ABL inhibitor
 - Nilotinib (Tasigna) is an imatinib derivative with 30-fold potency compared to imatinib
- Resistance to TKI therapy may result from acquired point mutations within the ABL kinase domain, *BCR-ABL1* amplification, low bioavailability, and/or quiescent CML stem cells
 - Resistance may be overcome with dose adjustments or a change in therapy
 - Newer drugs may be useful when resistance develops, including bosutinib (Bosulif) and ponatinib (Iclusig)
- Use of massively parallel sequencing (next generation sequencing) improves the ability to detect low-level clones across larger sections of the gene

Acute Lymphoblastic Leukemia

BCR-ABL1 mutations are present in a subset of ALL patients and are more common in adults than children. Detection of mutations in *BCR-ABL1* is important in helping to determine potential response to TKI therapy.

Genetics

Gene Fusion

BCR-ABL1

Mutations

- >130 mutations
- Four regions tested: adenosine triphosphate binding-loop (P-loop), drug-binding sites, catalytic domain, and activation loop

Test Interpretation

Analytical Sensitivity

- Variant class: single nucleotide variant (SNV)
- Number of variants tested: 396
- Positive percent agreement (PPA): 96.3%
- PPA, 95% tolerance at 95% reliability: 94.3-98.0%

Featured ARUP Testing

[BCR-ABL1 Mutation Analysis for Tyrosine Kinase Inhibitor Resistance by Next Generation Sequencing 2008420](#)

Method: Massively Parallel Sequencing

- Order only for patients with an established diagnosis of a *BCR-ABL1*-positive leukemia
- Use to determine if a mutation is present that would interfere with response to TKI therapy in Ph+ ALL or CML
 - Detects all common mutations, including T315I
 - Higher sensitivity than traditional Sanger sequencing techniques
 - Offers coverage of SH2, SH3, and kinase domain

Results

Result	Interpretation
Detected	Mutation detected in the SH2, SH3, or kinase domain (ABL1 amino acid residues 46-542)
Not amplified	Multiple attempts to amplify the <i>BCR-ABL1</i> translocation were unsuccessful by PCR
Not detected	No mutation detected

PCR, polymerase chain reaction

Limitations

- A negative result does not exclude mutations below the level of detection or outside the sequenced region
- Sensitivity of this assay may be limited, and sequencing may not be possible in patient samples containing low tumor burden (ie, low levels of *BCR-ABL1* fusion transcript by international scale % or normalized copy number)
- Not intended to be used for detection or quantification of *BCR-ABL1* fusion transcripts

Related Information

[Acute Lymphoblastic Leukemia - ALL](#)
[Acute Lymphoblastic Leukemia FISH Panels](#)
[BCR-ABL1 \(BCR::ABL1\) Qualitative and Quantitative Testing](#)
[Chronic Myeloid Leukemia - CML](#)
[TPMT and NUDT15](#)

ARUP Laboratories is a nonprofit enterprise of the University of Utah and its Department of Pathology. 500 Chipeta Way, Salt Lake City, UT 84108
(800) 522-2787 | (801) 583-2787 | aruplab.com | arupconsult.com